Cargando…

Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer

PURPOSE: Estrogen plays a critical role in the invasiveness and metastasis of non-small cell lung cancer (NSCLC) through estrogen receptor β (ERβ). However, the antimetastatic effect of the ERβ antagonist fulvestrant was still limited in NSCLC patients. Recently, Toll-like receptor 4 (TLR4) signalin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, S., Liao, Y., Qiu, W., Li, L., Li, D., Cao, X., Ai, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505887/ https://www.ncbi.nlm.nih.gov/pubmed/32367494 http://dx.doi.org/10.1007/s12094-020-02353-3

Ejemplares similares

The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
por: Pan, Long-Fei, et al.
Publicado: (2017)

TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury
por: Zhang, Yide, et al.
Publicado: (2015)

TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice
por: Hua, Fang, et al.
Publicado: (2015)

TAK-242, a toll-like receptor 4 antagonist, against brain injury by alleviates autophagy and inflammation in rats
por: Feng, Yan, et al.
Publicado: (2023)

Selective inhibition of Toll-like receptor 4 signaling by the small molecule TAK-242
por: Kawamoto, T, et al.
Publicado: (2006)

TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency
por: Fukushima, Hidehiko, et al.
Publicado: (2020)

Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress
por: Gárate, Iciar, et al.
Publicado: (2014)

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis
por: Bhattacharyya, Swati, et al.
Publicado: (2018)

Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug
por: Samarpita, Snigdha, et al.
Publicado: (2020)

TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice
por: Ono, Yuko, et al.
Publicado: (2020)

CLI-095 decreases atherosclerosis by modulating foam cell formation in apolipoprotein E-deficient mice
por: WANG, XIAO-QING, et al.
Publicado: (2016)

Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model
por: Fellner, Avi, et al.
Publicado: (2017)

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression
por: Tang, Hexiao, et al.
Publicado: (2014)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

Sulfonamide Prodrugs with a Two-Stage Release Mechanism for the Efficient Delivery of the TLR4 Antagonist TAK-242
por: Kostyo, Jessica H., et al.
Publicado: (2022)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

TAK-242, a novel Toll-like receptor 4 signal transduction inhibitor, protects mice in Escherichia coli-induced and lipoteichoic acid-induced lethality models
por: Ii, M, et al.
Publicado: (2006)

TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipidinduced inflammation and insulin resistance in muscle cells
por: Hussey, Sophie E., et al.
Publicado: (2012)

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis
por: Liu, Sujie, et al.
Publicado: (2022)

TAK-242 ameliorates epileptic symptoms in mice by inhibiting the TLR4/NF-κB signaling pathway
por: Dong, Jibo, et al.
Publicado: (2022)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Prenatal exposure to TAK242 affects the childhood autism in offspring in animal models of autism spectrum disorder
por: Xu, Xiaoyan, et al.
Publicado: (2017)

TAK242 suppresses the TLR4 signaling pathway and ameliorates DCD liver IRI in rats
por: Zhong, Xiang, et al.
Publicado: (2019)

TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesity
por: Moser, V. Alexandra, et al.
Publicado: (2018)

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
por: Huang, Yuan, et al.
Publicado: (2017)

Antimetastatic effects of cordycepin mediated by the inhibition of mitochondrial activity and estrogen-related receptor α in human ovarian carcinoma cells
por: Wang, Chia-Woei, et al.
Publicado: (2016)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Learning PowerCLI
por: Nieuwendijk, Robert van den
Publicado: (2016)

PowerCLI cookbook
por: Sellers, Philip
Publicado: (2015)

C++/CLI in Action
por: Sivakumar, Nishant
Publicado: (2007)

PowerCLI essentials: simplify and automate server administration tasks with PowerCLI
por: Halverson, Chris
Publicado: (2016)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS
por: Kapara, Anastasia, et al.
Publicado: (2021)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

Mastering PowerCLI: master PowerCLI to automate all aspects of VMware environments
por: Debnath, Sajal
Publicado: (2015)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Shared source CLI essentials
por: Stutz, David, et al.
Publicado: (2003)

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
por: Addo, S, et al.
Publicado: (2002)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ab8arf1p61aoor83foovfmlv63